Index RUT
P/E -
EPS (ttm) -4.50
Insider Own 11.02%
Shs Outstand 63.82M
Perf Week -3.10%
Market Cap 936.24M
Forward P/E -
EPS next Y -3.84
Insider Trans 7.26%
Shs Float 56.79M
Perf Month -6.20%
Income -218.12M
PEG -
EPS next Q -0.88
Inst Own 96.16%
Short Float 16.40%
Perf Quarter -17.31%
Sales 0.29M
P/S 3228.41
EPS this Y 31.55%
Inst Trans 19.03%
Short Ratio 10.16
Perf Half Y 6.61%
Book/sh 6.00
P/B 2.44
EPS next Y -5.52%
ROA -42.89%
Short Interest 9.31M
Perf Year -37.39%
Cash/sh 9.61
P/C 1.53
EPS next 5Y -
ROE -46.75%
52W Range 10.93 - 28.35
Perf YTD -32.64%
Dividend Est. -
P/FCF -
EPS past 5Y 20.35%
ROI -36.13%
52W High -48.25%
Beta 1.10
Dividend TTM -
Quick Ratio 23.99
Sales past 5Y -12.71%
Gross Margin -407.64%
52W Low 34.28%
ATR (14) 0.90
Dividend Ex-Date -
Current Ratio 23.99
EPS Y/Y TTM 3.36%
Oper. Margin -82595.49%
RSI (14) 47.68
Volatility 6.22% 5.90%
Employees 96
Debt/Eq 0.04
Sales Y/Y TTM -82.59%
Profit Margin -75737.85%
Recom 1.27
Target Price 36.47
Option/Short Yes / Yes
LT Debt/Eq 0.04
EPS Q/Q 50.75%
Payout -
Rel Volume 0.69
Prev Close 14.34
Sales Surprise -18.27%
EPS Surprise 27.46%
Sales Q/Q -26.53%
Earnings May 08 BMO
Avg Volume 917.03K
Price 14.67
SMA20 2.76%
SMA50 -9.33%
SMA200 -15.12%
Trades
Volume 635,267
Change 2.30%
Date
Action
Analyst
Rating Change
Price Target Change
May-09-24 Downgrade
Ladenburg Thalmann
Buy → Neutral
May-09-24 Downgrade
B. Riley Securities
Buy → Neutral
$25 → $20
Jun-14-23 Resumed
Credit Suisse
Outperform
$51
Jun-14-23 Initiated
BTIG Research
Buy
$46
May-30-23 Initiated
RBC Capital Mkts
Outperform
$44
Apr-17-23 Initiated
Wells Fargo
Overweight
$46
Mar-30-23 Initiated
Stifel
Buy
$49
Dec-19-22 Initiated
Needham
Buy
$45
Dec-19-22 Initiated
Cowen
Outperform
$45
Dec-16-22 Initiated
Credit Suisse
Outperform
$51
Dec-01-22 Initiated
H.C. Wainwright
Buy
$35
Jun-23-22 Initiated
B. Riley Securities
Buy
$25
Nov-18-21 Initiated
SVB Leerink
Outperform
$32
Oct-12-21 Initiated
Evercore ISI
Outperform
$40
Jan-25-21 Initiated
Ladenburg Thalmann
Buy
$40
Show Previous Ratings
May-10-24 08:00AM
May-09-24 03:02AM
May-08-24 11:54AM
08:36AM
08:25AM
07:00AM
Loading…
07:00AM
May-03-24 08:00AM
Apr-29-24 08:00AM
Apr-04-24 04:01PM
Mar-06-24 04:01PM
Mar-05-24 08:00AM
Feb-28-24 09:55AM
Feb-27-24 04:01PM
Feb-16-24 08:00AM
Feb-06-24 04:01PM
10:00PM
Loading…
Jan-17-24 10:00PM
04:01PM
Jan-08-24 08:00AM
Jan-04-24 08:00AM
Dec-18-23 07:00AM
Nov-21-23 08:00AM
Nov-13-23 05:00PM
04:01PM
Nov-08-23 08:00AM
Nov-03-23 08:00AM
Oct-30-23 08:30AM
Oct-26-23 08:00AM
Sep-25-23 08:00AM
Sep-07-23 08:00AM
Aug-08-23 04:01PM
04:01PM
Loading…
Aug-04-23 04:01PM
Jul-10-23 04:01PM
Jul-06-23 04:05PM
Jun-13-23 08:00AM
Jun-05-23 04:05PM
May-09-23 04:01PM
May-08-23 08:00AM
May-04-23 04:05PM
May-02-23 08:00AM
Apr-20-23 01:41PM
08:00AM
Apr-16-23 09:50AM
Apr-13-23 06:52AM
Apr-12-23 08:00AM
Apr-04-23 04:05PM
Mar-08-23 07:00AM
Mar-07-23 08:00AM
Mar-03-23 04:05PM
Mar-01-23 08:00AM
Feb-28-23 08:00AM
Feb-07-23 08:00AM
Feb-06-23 07:00AM
Feb-02-23 04:05PM
Jan-08-23 08:00AM
Jan-05-23 04:05PM
Jan-03-23 08:00AM
Dec-21-22 07:00AM
Dec-07-22 04:05PM
Nov-28-22 07:00AM
Nov-16-22 05:10AM
Nov-14-22 07:01AM
06:59AM
Nov-08-22 07:05AM
07:00AM
Oct-22-22 02:04PM
Oct-12-22 08:12AM
Sep-02-22 08:00AM
Aug-31-22 08:00AM
(Investor's Business Daily)
Aug-25-22 04:03PM
Aug-17-22 08:59AM
(Simply Wall St.) -10.67%
06:00AM
Aug-15-22 04:35PM
(Investor's Business Daily) +49.36%
04:01PM
02:17PM
(Schaeffer's Investment Research)
07:02AM
06:59AM
Aug-08-22 08:00AM
Aug-05-22 08:00AM
Jul-08-22 08:00AM
Jun-23-22 07:00AM
Jun-03-22 08:00AM
Jun-01-22 08:00AM
May-12-22 04:05PM
May-03-22 08:00AM
Apr-06-22 08:00AM
Apr-04-22 04:05PM
Mar-21-22 04:05PM
Mar-14-22 06:36PM
04:05PM
Mar-10-22 04:05PM
10:33AM
Mar-03-22 04:16PM
Feb-14-22 08:00AM
Jan-31-22 07:00AM
Jan-04-22 07:00AM
Dec-20-21 07:00AM
Nov-30-21 08:00AM
Nov-15-21 07:00AM
Nov-04-21 04:05PM
Nov-03-21 04:05PM
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fairmount Funds Management LLC Director Jan 22 '24 Buy 21.00 476,190 9,999,990 1,839,954 Jan 24 06:44 PM Meisner Lara Chief Legal Officer Jun 16 '23 Option Exercise 23.03 27 622 29,998 Jun 20 05:23 PM Meisner Lara Chief Legal Officer Jun 16 '23 Sale 28.35 27 765 29,971 Jun 20 05:23 PM Meisner Lara Chief Legal Officer Jun 15 '23 Option Exercise 23.03 2,269 52,255 32,240 Jun 20 05:23 PM Meisner Lara Chief Legal Officer Jun 15 '23 Sale 28.02 2,269 63,577 29,971 Jun 20 05:23 PM Meisner Lara Chief Legal Officer Jun 06 '23 Option Exercise 18.51 5,126 94,882 35,097 Jun 06 07:41 PM Meisner Lara Chief Legal Officer Jun 06 '23 Sale 25.02 5,126 128,253 29,971 Jun 06 07:41 PM Meisner Lara Chief Legal Officer Jun 05 '23 Option Exercise 18.51 499 9,236 30,470 Jun 06 07:41 PM Meisner Lara Chief Legal Officer Jun 05 '23 Sale 25.03 499 12,490 29,971 Jun 06 07:41 PM Meisner Lara Chief Legal Officer Jun 02 '23 Option Exercise 14.00 1,875 26,250 31,846 Jun 06 07:41 PM Meisner Lara Chief Legal Officer Jun 02 '23 Sale 24.21 1,875 45,394 29,971 Jun 06 07:41 PM
Index -
P/E -
EPS (ttm) -5.89
Insider Own 26.41%
Shs Outstand 29.35M
Perf Week 16.22%
Market Cap 820.04M
Forward P/E -
EPS next Y -2.57
Insider Trans 0.00%
Shs Float 21.60M
Perf Month 10.57%
Income -42.36M
PEG -
EPS next Q -0.58
Inst Own 52.05%
Short Float 9.94%
Perf Quarter 19.61%
Sales 2.25M
P/S 364.46
EPS this Y 72.98%
Inst Trans 5.07%
Short Ratio 13.07
Perf Half Y 142.96%
Book/sh 12.70
P/B 2.20
EPS next Y -12.55%
ROA -18.18%
Short Interest 2.15M
Perf Year 175.09%
Cash/sh 12.85
P/C 2.17
EPS next 5Y -
ROE -18.82%
52W Range 6.58 - 33.77
Perf YTD 168.65%
Dividend Est. -
P/FCF -
EPS past 5Y 29.95%
ROI -11.36%
52W High -17.26%
Beta 1.87
Dividend TTM -
Quick Ratio 42.52
Sales past 5Y -11.19%
Gross Margin 89.84%
52W Low 324.62%
ATR (14) 2.07
Dividend Ex-Date -
Current Ratio 42.52
EPS Y/Y TTM 73.28%
Oper. Margin -2306.70%
RSI (14) 63.09
Volatility 7.96% 8.34%
Employees 53
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -1878.40%
Recom 1.17
Target Price 50.83
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q 93.04%
Payout -
Rel Volume 0.59
Prev Close 26.01
Sales Surprise 88.28%
EPS Surprise -23.29%
Sales Q/Q -
Earnings May 09 AMC
Avg Volume 164.29K
Price 27.94
SMA20 19.55%
SMA50 10.05%
SMA200 67.54%
Trades
Volume 96,629
Change 7.42%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
Stifel
Buy
$44
Dec-26-23 Initiated
Jefferies
Buy
$22
Nov-22-23 Initiated
Wedbush
Outperform
$23
Oct-30-23 Initiated
Guggenheim
Buy
$45
Sep-28-23 Initiated
Raymond James
Outperform
$24
Aug-25-22 Downgrade
Goldman
Buy → Neutral
$2
Jan-06-22 Upgrade
Goldman
Neutral → Buy
$7 → $8
Aug-20-21 Resumed
Goldman
Neutral
$7
Aug-03-21 Downgrade
JP Morgan
Overweight → Neutral
$16 → $7
Jul-22-21 Reiterated
B. Riley Securities
Buy
$21 → $19
Jun-29-21 Initiated
Cantor Fitzgerald
Overweight
$20
Jun-15-21 Initiated
BTIG Research
Buy
$20
May-18-21 Initiated
B. Riley Securities
Buy
$21
Jan-07-21 Initiated
Mizuho
Buy
$16
Jun-08-20 Upgrade
Goldman
Neutral → Buy
$15
Mar-25-19 Downgrade
Goldman
Buy → Neutral
$17 → $16
Mar-15-19 Initiated
Raymond James
Outperform
Jul-16-18 Initiated
Wedbush
Outperform
$22
Jul-16-18 Initiated
JP Morgan
Overweight
$18
Jul-16-18 Initiated
Goldman
Buy
$18
Show Previous Ratings
May-09-24 10:56PM
04:01PM
May-08-24 04:30PM
May-03-24 04:30PM
Apr-11-24 07:30AM
04:30PM
Loading…
Apr-05-24 04:30PM
Mar-21-24 10:54PM
04:01PM
Mar-07-24 04:30PM
Feb-26-24 07:00AM
Feb-23-24 08:00AM
Jan-31-24 04:05PM
Jan-22-24 07:30AM
Jan-02-24 08:30AM
Dec-14-23 07:04AM
04:05PM
Loading…
Nov-29-23 04:05PM
Nov-09-23 04:05PM
Sep-14-23 05:04PM
Aug-14-23 01:35PM
(American City Business Journals)
May-03-23 04:19PM
07:00AM
Mar-31-23 04:10PM
06:09AM
Mar-27-23 10:20AM
Feb-09-23 01:24PM
(American City Business Journals)
10:13AM
Feb-03-23 01:35PM
(American City Business Journals) +51.66%
Feb-02-23 04:05PM
05:58AM
(American City Business Journals)
Jan-25-23 04:05PM
07:39AM
Loading…
Dec-21-22 07:39AM
Dec-20-22 11:20AM
09:00AM
Dec-13-22 05:56AM
Dec-12-22 04:30PM
08:00AM
Nov-03-22 09:01AM
09:01AM
Nov-01-22 08:00AM
Oct-17-22 12:16PM
Sep-23-22 09:15AM
Aug-17-22 08:00AM
Aug-04-22 08:00AM
Aug-02-22 08:00AM
Jul-17-22 09:04AM
May-16-22 12:29PM
09:35AM
08:00AM
May-10-22 11:54AM
Apr-14-22 04:41PM
(American City Business Journals) -7.05%
12:15PM
08:00AM
Mar-08-22 08:00AM
Mar-03-22 08:00AM
Feb-07-22 09:35AM
Jan-18-22 07:00AM
Jan-10-22 08:00AM
Jan-05-22 08:00AM
Dec-14-21 09:00AM
Nov-10-21 06:20AM
Nov-08-21 09:24AM
Nov-04-21 09:10AM
09:09AM
Oct-04-21 08:00AM
Sep-21-21 08:00AM
Sep-15-21 08:00AM
Aug-09-21 06:20AM
Aug-05-21 08:00AM
Aug-03-21 05:30PM
08:00AM
Aug-01-21 11:50AM
Jul-30-21 09:20PM
11:14AM
Jul-28-21 07:39PM
Jul-26-21 08:16PM
Jul-23-21 11:00AM
10:14AM
Jul-21-21 10:30PM
03:46PM
08:47AM
08:00AM
Jul-14-21 10:00AM
Jul-06-21 08:00AM
Jun-17-21 09:43AM
Jun-14-21 08:00AM
Jun-04-21 09:00AM
Jun-03-21 08:00AM
May-14-21 08:00AM
May-12-21 10:00AM
10:00AM
May-06-21 08:00AM
May-03-21 06:41AM
Apr-19-21 08:00AM
Mar-25-21 08:00AM
Mar-15-21 08:00AM
Mar-09-21 08:00AM
Mar-03-21 08:00AM
Feb-27-21 08:08AM
Feb-08-21 08:00AM
Feb-01-21 04:30AM
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fairmount Funds Management LLC Director Sep 29 '23 Buy 13.63 24,670 336,252 1,928,503 Oct 03 04:00 PM Fairmount Funds Management LLC Director Sep 26 '23 Buy 13.15 30,000 394,500 1,903,833 Sep 28 05:09 PM Randhawa Simrat Chief Medical Officer Sep 22 '23 Buy 13.20 2,000 26,400 4,000 Sep 25 04:15 PM Randhawa Simrat Chief Medical Officer Sep 21 '23 Buy 13.20 2,000 26,400 2,000 Sep 25 04:15 PM Fairmount Funds Management LLC Director Sep 19 '23 Buy 13.20 30,000 396,000 1,873,833 Sep 21 04:23 PM Fairmount Funds Management LLC Director Sep 13 '23 Buy 11.76 9,367 110,156 1,843,833 Sep 13 09:17 PM Fairmount Funds Management LLC Director Sep 12 '23 Buy 10.85 14,887 161,524 1,834,466 Sep 13 09:17 PM
Index RUT
P/E -
EPS (ttm) -
Insider Own 7.06%
Shs Outstand 37.17M
Perf Week 3.41%
Market Cap 2.01B
Forward P/E -
EPS next Y -3.22
Insider Trans 0.00%
Shs Float 34.56M
Perf Month 1.75%
Income -
PEG -
EPS next Q -0.62
Inst Own 96.39%
Short Float 14.02%
Perf Quarter 50.84%
Sales -
P/S -
EPS this Y 22.62%
Inst Trans -
Short Ratio 7.09
Perf Half Y 255.97%
Book/sh 13.71
P/B 3.94
EPS next Y -23.74%
ROA -
Short Interest 4.84M
Perf Year -
Cash/sh 21.95
P/C 2.46
EPS next 5Y -
ROE -
52W Range 14.19 - 72.29
Perf YTD 93.27%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -
52W High -25.30%
Beta -
Dividend TTM -
Quick Ratio 38.08
Sales past 5Y 0.00%
Gross Margin -
52W Low 280.55%
ATR (14) 3.22
Dividend Ex-Date -
Current Ratio 38.08
EPS Y/Y TTM -
Oper. Margin -
RSI (14) 53.39
Volatility 5.44% 6.15%
Employees -
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 84.83
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -158.66%
Payout -
Rel Volume 2.60
Prev Close 52.73
Sales Surprise -
EPS Surprise -9.08%
Sales Q/Q -
Earnings May 13 BMO
Avg Volume 683.43K
Price 54.00
SMA20 7.08%
SMA50 -6.17%
SMA200 64.38%
Trades
Volume 1,776,538
Change 2.41%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-24 Initiated
BofA Securities
Buy
$80
Dec-20-23 Initiated
BTIG Research
Buy
$43
Aug-08-23 Initiated
Wedbush
Outperform
$40
Aug-08-23 Initiated
TD Cowen
Outperform
Aug-08-23 Initiated
Stifel
Buy
$34
Aug-08-23 Initiated
Jefferies
Buy
$29
Aug-08-23 Initiated
Guggenheim
Buy
$29
May-13-24 01:53PM
07:42AM
07:00AM
May-10-24 10:13AM
May-08-24 01:28PM
08:00AM
Loading…
May-06-24 08:00AM
Apr-03-24 07:49AM
Mar-28-24 11:01AM
Mar-25-24 07:00AM
07:00AM
Mar-12-24 04:01PM
Mar-07-24 06:49PM
Mar-05-24 10:53PM
04:23PM
04:16PM
(Investor's Business Daily)
07:35AM
Loading…
07:35AM
(Investor's Business Daily)
07:35AM
(Investor's Business Daily)
06:10AM
06:00AM
06:00AM
Mar-04-24 04:01PM
Jan-02-24 07:30AM
Nov-15-23 04:44AM
Nov-13-23 07:30AM
Oct-30-23 08:00AM
Oct-23-23 02:50AM
Sep-27-23 08:42AM
Sep-14-23 07:30AM
Aug-29-23 08:00AM
Aug-28-23 07:30AM
07:30AM
Loading…
Aug-21-23 07:30AM
Aug-10-23 02:29PM
Aug-08-23 10:02AM
Aug-07-23 07:30AM
Aug-04-23 06:30PM
Aug-02-23 07:30AM
Jul-18-23 04:01PM
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fairmount Funds Management LLC Director Jul 13 '23 Buy 17.00 2,941,176 49,999,992 1,992,734 Jul 17 08:00 PM Shah Nimish P Director Jul 13 '23 Buy 17.00 1,750,000 29,750,000 1,750,000 Jul 17 08:00 PM
Index RUT
P/E -
EPS (ttm) -2.47
Insider Own 11.55%
Shs Outstand 86.12M
Perf Week -5.28%
Market Cap 702.73M
Forward P/E -
EPS next Y -2.19
Insider Trans 0.00%
Shs Float 84.57M
Perf Month 13.08%
Income -212.17M
PEG -
EPS next Q -0.55
Inst Own 85.28%
Short Float 14.24%
Perf Quarter 34.62%
Sales 0.00M
P/S -
EPS this Y 8.13%
Inst Trans 4.33%
Short Ratio 5.81
Perf Half Y 6.52%
Book/sh 2.09
P/B 3.51
EPS next Y 1.37%
ROA -57.40%
Short Interest 12.04M
Perf Year -36.25%
Cash/sh 4.56
P/C 1.61
EPS next 5Y -
ROE -65.70%
52W Range 3.67 - 13.50
Perf YTD 25.00%
Dividend Est. -
P/FCF -
EPS past 5Y 15.33%
ROI -48.28%
52W High -45.56%
Beta 1.59
Dividend TTM -
Quick Ratio 12.05
Sales past 5Y -6.78%
Gross Margin -
52W Low 100.27%
ATR (14) 0.50
Dividend Ex-Date -
Current Ratio 12.05
EPS Y/Y TTM -6.72%
Oper. Margin 0.00%
RSI (14) 54.69
Volatility 7.45% 6.85%
Employees 164
Debt/Eq 0.04
Sales Y/Y TTM -
Profit Margin -
Recom 1.36
Target Price 17.00
Option/Short Yes / Yes
LT Debt/Eq 0.04
EPS Q/Q -12.83%
Payout -
Rel Volume 0.31
Prev Close 7.35
Sales Surprise -
EPS Surprise -20.51%
Sales Q/Q -
Earnings May 07 BMO
Avg Volume 2.07M
Price 7.35
SMA20 5.24%
SMA50 8.39%
SMA200 -8.05%
Trades
Volume 649,372
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-26-24 Downgrade
Robert W. Baird
Outperform → Neutral
$14 → $8
Feb-08-24 Initiated
Citigroup
Buy
$11
Dec-11-23 Downgrade
Wedbush
Outperform → Neutral
$5
Dec-08-23 Initiated
JP Morgan
Overweight
$18
Apr-28-23 Initiated
Robert W. Baird
Outperform
$20
Mar-27-23 Resumed
H.C. Wainwright
Buy
$28
Dec-14-22 Initiated
Needham
Buy
$24
Jun-28-22 Initiated
Guggenheim
Buy
$15
Oct-11-21 Initiated
H.C. Wainwright
Buy
$25
Jun-09-21 Resumed
Jefferies
Buy
$20
Dec-23-20 Initiated
Piper Sandler
Overweight
$22
Oct-14-20 Initiated
Ladenburg Thalmann
Buy
$4
Show Previous Ratings
May-07-24 01:52PM
08:00AM
Apr-09-24 09:00AM
Mar-13-24 07:06AM
Feb-28-24 04:32AM
08:00AM
Loading…
Feb-26-24 08:00AM
Feb-22-24 02:30PM
Feb-14-24 07:00AM
Feb-05-24 09:00AM
Jan-09-24 08:00AM
Jan-02-24 08:00AM
Dec-11-23 07:55AM
Dec-09-23 01:30PM
Dec-07-23 09:00AM
Dec-04-23 08:00AM
08:00AM
Loading…
Nov-29-23 08:00AM
Nov-02-23 09:00AM
Oct-14-23 12:30PM
Aug-13-23 08:51AM
Aug-08-23 08:00AM
Jul-10-23 07:35PM
Jun-09-23 04:01PM
Jun-07-23 09:00AM
Jun-06-23 08:25PM
04:05PM
Jun-03-23 02:15PM
May-23-23 08:00AM
May-09-23 08:00AM
Apr-17-23 09:00AM
Apr-12-23 08:00AM
08:00AM
Loading…
Mar-14-23 08:00AM
Feb-01-23 08:00AM
Jan-11-23 11:03AM
Jan-09-23 08:00AM
Jan-05-23 08:00AM
Dec-11-22 05:30PM
Dec-05-22 08:00AM
Nov-28-22 04:15PM
Nov-14-22 07:00AM
Nov-09-22 08:00AM
Nov-03-22 09:05AM
Oct-26-22 07:00AM
Aug-14-22 12:21PM
Aug-09-22 07:00AM
Aug-04-22 11:22AM
(Simply Wall St.) +12.58%
Jun-20-22 11:09AM
Jun-16-22 04:01PM
Jun-13-22 09:48PM
06:00AM
Jun-10-22 07:00AM
Jun-06-22 10:15AM
Jun-02-22 08:00AM
May-12-22 10:00AM
May-10-22 07:00AM
May-06-22 08:00AM
Apr-11-22 07:00AM
Mar-29-22 07:00AM
Mar-15-22 07:00AM
Mar-08-22 05:10PM
Feb-01-22 05:29AM
Jan-05-22 07:00AM
Nov-22-21 07:00AM
Nov-10-21 07:00AM
Nov-02-21 07:00AM
Oct-29-21 09:46AM
Oct-12-21 07:59PM
Oct-07-21 09:00AM
Oct-01-21 07:00AM
Aug-16-21 07:00AM
Jul-27-21 07:00AM
Jul-13-21 11:11AM
Jun-29-21 07:00AM
Jun-15-21 11:37AM
May-26-21 07:00AM
May-12-21 07:00AM
May-03-21 07:00AM
Apr-06-21 07:00AM
Mar-17-21 02:27AM
Mar-16-21 07:00AM
Feb-22-21 07:00AM
Feb-18-21 07:00AM
Feb-11-21 07:00AM
Dec-04-20 05:16PM
Dec-01-20 11:08PM
Nov-30-20 04:01PM
07:00AM
Nov-20-20 07:00AM
Nov-18-20 09:00AM
Nov-12-20 04:30PM
Nov-09-20 07:00AM
Nov-05-20 07:00AM
Oct-26-20 07:00AM
Apr-01-20 01:42AM
(Thomson Reuters StreetEvents) -6.36%
Nov-13-19 06:22PM
(Thomson Reuters StreetEvents)
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fairmount Funds Management LLC 10% Owner Jun 09 '23 Buy 12.00 800,000 9,600,000 3,272,124 Jun 13 04:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite